Patent SG-11201406625X-A (SG)
Title: Anti-fcrn antibodies
Inventor: FINNEY HELENE MARGARET
IPC: G01N33/53
Filed: 2013-05-13
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 6 February 2014 (06.02.2014) WIPOIPCT (10) International Publication Number WO 2014/019727 A1 (51) International Patent Classification: C07K16/28 (2006.01) G01N33/53 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2013/059802 13 May 2013 (13.05.2013) English English (30) Priority Data: 1208370.5 14 May 2012 (14.05.2012) GB (71) Applicant: UCB PHARMA S.A. [BE/BE]; 60 Allee de la Recherche, B-1070 Brussels (BE). (72) Inventors: FINNEY, Helene Margaret; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). LAWSON, Alastair David Griffiths; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). SHAW, Stevan Graham; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). SMITH, Bryan John; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). TYSON, Kerry Louise; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). KEVORKIAN, Lara; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). (74) Agent: THOMPSON, John; UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: ANTI-FCRN ANTIBODIES Figure 18 Change in plasma IgG levels in cynomolgus monkeys treated with 30 mg/Kg 1519.g57 IgG4P on day 0 followed by 5mg/Kg 1519.g57 lgG4P daily for 41 days l> CJ l> o\ T-H © T-H O CJ — Cyno 9 = Cyno 10 Cyno 11 — Cyno 12 • Dose Time (days post dose) (57) Abstract: The disclosure relates antibodies to specific to FcRn, formulations comprising the same, use of each in therapy, pro­ cesses for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.